** Shares of drug developer Adaptimmune Therapeutics
rise ~3% to 81 cents
** Co says its cell therapy being developed to treat two rare types of cancers met the main goal of a mid-stage study
** The therapy, lete-cel, helped 42% of study patients achieve partial or complete response to the treatment - ADAP
** Co plans to begin application process for lete-cel in 2025 for the treatment of both synovial sarcoma and myxoid/round cell liposarcoma (MRCLS) - ADAP
** Synovial sarcoma is a cancer in the soft tissues that most often affects young people and MRCLS is a cancer that grows in the cells that store fat in the body
** Including session gains, stock up ~2% YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。